Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520767 · ClinicalTrials.gov registry record · Phase 2
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
A Phase 2 study of Light Chain Deposition Disease and Primary Systemic Amyloidosis, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 7
- Study locations
NCT00520767 is a Phase 2 study of Light Chain Deposition Disease and Primary Systemic Amyloidosis that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 35 participants, below the 572-participant average among 4 other Light Chain Deposition Disease trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00520767, a Phase 2 study of Light Chain Deposition Disease and Primary Systemic Amyloidosis, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 7
- Study locations
Study Summary
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease. PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients with primary amyloidosis or light chain deposition disease.
Conditions Studied
Interventions
- GENETIC microarray analysis
- DRUG dexamethasone
- DRUG melphalan
- OTHER flow cytometry
- DRUG bortezomib
Study Locations (7)
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
- Providence Cancer Institute at Providence Hospital - Southfield Campus - Southfield
Colorado
- Rocky Mountain Cancer Centers/Rocky Mountain Blood & Marrow Transplant Program - Denver
Massachusetts
- Boston University Cancer Research Center - Boston
North Carolina
- Duke Comprehensive Cancer Center - Durham
Pennsylvania
- UPMC Cancer Centers - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-09 |
| Est. Completion | 2019-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520767
The ClinicalTrials.gov registry entry for NCT00520767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 572-participant average among 4 other Light Chain Deposition Disease trials with a reported enrollment target (94% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Light Chain Deposition Disease appearing as the primary indexed condition, and to 5 interventions - of which microarray analysis is the first listed.
NCT00520767 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Michigan, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00520767 about?
NCT00520767 is a clinical study titled "Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease". RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease. PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients w...
What is the current status of trial NCT00520767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2007-09. Estimated completion is 2019-06-06.
What conditions does trial NCT00520767 study?
This clinical trial studies the following conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis.
What interventions are being tested in trial NCT00520767?
The interventions under investigation include: microarray analysis (GENETIC), dexamethasone (DRUG), melphalan (DRUG), flow cytometry (OTHER), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00520767?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00520767 being conducted?
This trial has 7 study locations across Colorado, Massachusetts, Michigan, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Light Chain Deposition Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
-
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 3
-
Rifaximin in Patients With Monoclonal Gammopathy
ACTIVE NOT RECRUITING · Phase 1
-
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.